Alumend is conducting an early-stage clinical study in New Zealand to test a device that can be used to help treat patients with peripheral arterial disease. The Sioux Falls, S.D.-based startup aims to refine the technology after the initial trial and advance it to U.S. clinical studies, founding member Ron Utecht said at a biotech conference in Chicago.

Related Summaries